Y-mAbs Therapeutics Inc (NAS:YMAB)
$ 15.46 -0.07 (-0.45%) Market Cap: 689.05 Mil Enterprise Value: 612.52 Mil PE Ratio: 0 PB Ratio: 7.23 GF Score: 53/100

Q2 2022 Y-mAbs Therapeutics Inc Earnings Call Transcript

Aug 09, 2022 / 01:00PM GMT
Release Date Price: $17.89 (-4.33%)
Operator

Good morning, and welcome to the Y-mAbs Therapeutics, Inc.'s Earnings Conference Call for the Second Quarter 2022. Today's conference is being recorded.

Let me quickly remind you that the following discussion contains certain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Because forward-looking statements involve risks and uncertainties, they are not guarantees of future performance and actual results may differ materially from those expressed or implied by these forward-looking statements due to a variety of factors, including those risk factors discussed in the company's quarterly report on Form 10-Q for the fiscal second quarter ended June 30, 2022, as filed with the SEC on August 8, 2022.

At this time, I would like to turn the conference over to Thomas Gad, the company's Founder, Interim CEO and President. Please go ahead sir.

Thomas Gad
Y-mAbs Therapeutics, Inc. - Founder, Interim CEO, President, Head of Business Development & Strategy and Director

Thank you. Good morning, everybody,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot